The world health organization has advised against antibody treatment for Covid-19 patients. They replaced previous recommendations for their use. The new advisory is based on emerging proof from laboratory studies that these drugs are not likely to work against the variants which are active now says the world health body.
The statement of WHO the three drugs used treat arthritis IL-6 receptor blockers Tocilizumab or Sarilumab and JAK inhibitor Baricitinib may now be combined, in addition to combined Corticosteroids in patients with severe or critical Covid-19.
In its updated guidance for Covid treatment published in the british medical journal. WHO has also made a conditional recommendation against its use in for patients with critical Covid-19.
WHO director-general Tedros Adhanom Ghebreyesus had said on Wednesday the number of Covid deaths worldwide last week was the lowest reported since march 2020.
The forming of eighth update of WHOs living guidelines on therapeutics and Covid-19 are based on evidence from seven trials involving over 4000 patients with non-severe, severe and critical Covid.
The organization is discussed with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics. The access to Covid-19 tool accelerator (ACT-A) therapeutics pillar has been engaging with pharmaceutical companies to seek comprehensive access plans for low-and middle-income countries.
